Selected donor CD34 + cell boosts for salvage treatment of poor graft function following allogeneic hematopoietic stem cell transplantation in primary myelofibrosis: 3 cases report
10.3760/cma.j.cn121090-20240117-00029
- VernacularTitle:供者CD34 +细胞纯化输注挽救治疗原发性骨髓纤维化异基因造血干细胞移植后移植物功能不良3例
- Author:
Haixia SHI
1
;
Huixia LIU
;
Daolin WEI
;
Jun ZHU
;
Shan SHAO
;
Ying JIANG
;
Chun WANG
;
Chuxian ZHAO
Author Information
1. 上海闸新中西医结合医院血液科，上海 200443
- From:
Chinese Journal of Hematology
2024;45(8):785-788
- CountryChina
- Language:Chinese
-
Abstract:
A retrospective analysis was conducted on three patients with primary myelofibrosis who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital from 2020 to 2023. They subsequently developed poor graft function. The patients received selected donor CD34 + cell boosts as salvage therapy. There were two male patients and one female patient, with a median age of 68 (39-69) years. The median time from allo-HSCT to the selected donor CD34 + cell boost was 83 (56-154) days. The median infusion of selected donor CD34 + cells was 7.67 (7.61-9.06) ×10 6/kg, with a CD34 + cell purity of 97.76% (96.50%-97.91%) and a recovery rate of 70% (42%-75%) . Hematological recovery was achieved in two cases. No acute GVHD was observed in any of the three patients. One case of moderate oral chronic GVHD was noted. Selected donor CD34 + cell boosts for the treatment of poor graft function after allo-HSCT in primary myelofibrosis was effective and no severe acute or chronic GVHD was observed.
